MX2016011975A - Metodos para reducir el riesgo cardiovascular. - Google Patents
Metodos para reducir el riesgo cardiovascular.Info
- Publication number
- MX2016011975A MX2016011975A MX2016011975A MX2016011975A MX2016011975A MX 2016011975 A MX2016011975 A MX 2016011975A MX 2016011975 A MX2016011975 A MX 2016011975A MX 2016011975 A MX2016011975 A MX 2016011975A MX 2016011975 A MX2016011975 A MX 2016011975A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- cardiovascular risk
- present
- lipoproteins
- patients
- Prior art date
Links
- 230000002526 effect on cardiovascular system Effects 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 102000004895 Lipoproteins Human genes 0.000 abstract 3
- 108090001030 Lipoproteins Proteins 0.000 abstract 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 2
- 229940122392 PCSK9 inhibitor Drugs 0.000 abstract 2
- 230000000923 atherogenic effect Effects 0.000 abstract 2
- 231100000682 maximum tolerated dose Toxicity 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 229960004539 alirocumab Drugs 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona métodos para tratar enfermedades y trastornos que están asociados con niveles elevados de lípidos y lipoproteínas. Los métodos de la presente invención comprenden administrar a un paciente con alto riesgo cardiovascular una composición farmacéutica que comprende un inhibidor de PCSK9. En ciertas modalidades, el inhibidor de PCSK9 es un anticuerpo anti-PCSK9 tal como el anticuerpo ejemplar denominado en este documento como mAb316P o alirocumab. Los métodos de la presente invención son útiles para el tratamiento de pacientes con alto riesgo cardiovascular con hipercolesterolemia y niveles elevados de otras lipoproteínas aterogénicas que no están controlados adecuadamente por la terapia de dosis máxima tolerada de estatina. En particular, los métodos de la presente invención son útiles para reducir el riesgo cardiovascular y la reducción de las lipoproteínas aterogénicas en pacientes con alto riesgo cardiovascular dentro de los 12 meses después de un evento por síndrome coronario agudo, a pesar de llevar una terapia de dosis máxima tolerada de estatinas.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461954094P | 2014-03-17 | 2014-03-17 | |
| US201462025400P | 2014-07-16 | 2014-07-16 | |
| US201462043182P | 2014-08-28 | 2014-08-28 | |
| EP15305293 | 2015-02-26 | ||
| PCT/US2015/020564 WO2015142668A1 (en) | 2014-03-17 | 2015-03-13 | Methods for reducing cardiovascular risk |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016011975A true MX2016011975A (es) | 2016-12-05 |
| MX380767B MX380767B (es) | 2025-03-12 |
Family
ID=52648962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016011975A MX380767B (es) | 2014-03-17 | 2015-03-13 | Métodos para reducir el riesgo cardiovascular. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20150284473A1 (es) |
| EP (2) | EP3119810B1 (es) |
| JP (3) | JP2017509624A (es) |
| KR (3) | KR20160132459A (es) |
| CN (3) | CN106794244A (es) |
| AU (3) | AU2015231713B2 (es) |
| CA (1) | CA2942549A1 (es) |
| EA (1) | EA039310B1 (es) |
| ES (1) | ES2978990T3 (es) |
| HU (1) | HUE066839T2 (es) |
| IL (1) | IL304491A (es) |
| MX (1) | MX380767B (es) |
| PL (1) | PL3119810T3 (es) |
| WO (1) | WO2015142668A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| SG177254A1 (en) | 2009-06-15 | 2012-02-28 | Ian Osterloh | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| KR20200133826A (ko) | 2011-01-28 | 2020-11-30 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | 특정 대상자 그룹의 치료 방법에 이용하기 위한 ｐｃｓｋ9에 대한 인간 항체 |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| HUE069234T2 (hu) | 2011-09-16 | 2025-02-28 | Regeneron Pharma | Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| WO2014197752A1 (en) | 2013-06-07 | 2014-12-11 | Regeneron Pharmaceuticals, Inc. | Methods fo inhibting atherosclerosis by administering an inhibitor of pcsk9 |
| US10428157B2 (en) | 2013-11-12 | 2019-10-01 | Sanofi Biotechnology | Dosing regimens for use with PCSK9 inhibitors |
| US20170198059A1 (en) * | 2014-07-14 | 2017-07-13 | Amgen Inc. | Crystalline antibody formulations |
| KR102482375B1 (ko) * | 2014-07-16 | 2022-12-29 | 사노피 바이오테크놀로지 | 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법 |
| AU2015289613B2 (en) | 2014-07-16 | 2021-07-01 | Regeneron Pharmaceuticals, Inc. | Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) |
| WO2016046684A1 (en) | 2014-09-23 | 2016-03-31 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
| MX2018002000A (es) | 2015-08-18 | 2018-06-19 | Regeneron Pharma | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. |
| JOP20190112A1 (ar) * | 2016-11-14 | 2019-05-14 | Amgen Inc | علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي |
| US10337070B2 (en) | 2017-01-12 | 2019-07-02 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| BR112019020148A2 (pt) | 2017-04-13 | 2020-05-05 | Cadila Healthcare Ltd | peptídeo |
| IL277127B2 (en) * | 2018-03-06 | 2025-11-01 | Sanofi Biotechnology | Use of pcsk9 inhibitor for reducing cardiovascular risk |
| EP3817768A4 (en) * | 2018-07-02 | 2022-07-06 | Abcentra, LLC | Compositions and methods for reduction of lipoprotein a formation and treatment of aortic valve sclerosis and aortic stenosis |
| CN112912071A (zh) * | 2018-08-17 | 2021-06-04 | 阿玛林制药爱尔兰有限公司 | 降低接受他汀类药物治疗的受试者对外周动脉血运重建的需求的方法 |
| DK4056176T3 (da) | 2018-09-24 | 2024-05-06 | Amarin Pharmaceuticals Ie Ltd | Fremgangsmåde til at reducere risikoen af kardiovaskulære hændelser hos et individ |
| MA54261B1 (fr) | 2019-01-18 | 2025-03-28 | Astrazeneca Ab | Inhibiteurs de pcsk9 et leurs procédés d'utilisation |
| EP4054625A4 (en) * | 2019-11-07 | 2026-01-07 | Medimmune Llc | Endothelial Lipase Antibodies for the Treatment of Cardiovascular Diseases |
| US12427134B2 (en) | 2019-11-12 | 2025-09-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| US20230312750A1 (en) * | 2019-11-18 | 2023-10-05 | Ad Pharmaceuticals Co., Ltd. | Anti-pcsk9 antibody and use thereof |
| WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| CN114848849B (zh) * | 2022-04-25 | 2023-11-17 | 南方科技大学 | Pcsk9蛋白抑制剂在治疗心血管疾病中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| KR20200133826A (ko) * | 2011-01-28 | 2020-11-30 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | 특정 대상자 그룹의 치료 방법에 이용하기 위한 ｐｃｓｋ9에 대한 인간 항체 |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
-
2015
- 2015-03-13 WO PCT/US2015/020564 patent/WO2015142668A1/en not_active Ceased
- 2015-03-13 KR KR1020167028383A patent/KR20160132459A/ko not_active Ceased
- 2015-03-13 MX MX2016011975A patent/MX380767B/es unknown
- 2015-03-13 CN CN201580024259.2A patent/CN106794244A/zh active Pending
- 2015-03-13 PL PL15712241.7T patent/PL3119810T3/pl unknown
- 2015-03-13 CN CN202210141115.7A patent/CN114642661A/zh active Pending
- 2015-03-13 EP EP15712241.7A patent/EP3119810B1/en active Active
- 2015-03-13 CA CA2942549A patent/CA2942549A1/en active Pending
- 2015-03-13 KR KR1020227039740A patent/KR20220157516A/ko not_active Ceased
- 2015-03-13 HU HUE15712241A patent/HUE066839T2/hu unknown
- 2015-03-13 JP JP2016556709A patent/JP2017509624A/ja active Pending
- 2015-03-13 US US14/657,192 patent/US20150284473A1/en not_active Abandoned
- 2015-03-13 AU AU2015231713A patent/AU2015231713B2/en active Active
- 2015-03-13 EA EA201691847A patent/EA039310B1/ru unknown
- 2015-03-13 KR KR1020247040556A patent/KR20250006995A/ko active Pending
- 2015-03-13 CN CN202210141133.5A patent/CN114558129A/zh active Pending
- 2015-03-13 ES ES15712241T patent/ES2978990T3/es active Active
- 2015-03-13 EP EP24160083.2A patent/EP4403213A3/en active Pending
-
2021
- 2021-02-19 AU AU2021201118A patent/AU2021201118A1/en not_active Abandoned
- 2021-10-19 US US17/504,921 patent/US20220144969A1/en not_active Abandoned
-
2022
- 2022-07-22 JP JP2022116854A patent/JP2022141868A/ja active Pending
-
2023
- 2023-07-16 IL IL304491A patent/IL304491A/en unknown
-
2024
- 2024-07-19 JP JP2024115429A patent/JP2024147744A/ja active Pending
- 2024-07-31 AU AU2024205254A patent/AU2024205254A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP4403213A2 (en) | 2024-07-24 |
| AU2015231713A1 (en) | 2016-10-20 |
| JP2017509624A (ja) | 2017-04-06 |
| HUE066839T2 (hu) | 2024-09-28 |
| US20220144969A1 (en) | 2022-05-12 |
| EP3119810B1 (en) | 2024-02-28 |
| IL304491A (en) | 2023-09-01 |
| US20150284473A1 (en) | 2015-10-08 |
| EA039310B1 (ru) | 2022-01-12 |
| CN114642661A (zh) | 2022-06-21 |
| CN106794244A (zh) | 2017-05-31 |
| WO2015142668A1 (en) | 2015-09-24 |
| JP2024147744A (ja) | 2024-10-16 |
| CN114558129A (zh) | 2022-05-31 |
| PL3119810T3 (pl) | 2024-07-15 |
| EP3119810C0 (en) | 2024-02-28 |
| ES2978990T3 (es) | 2024-09-23 |
| EA201691847A1 (ru) | 2017-01-30 |
| EP4403213A3 (en) | 2024-10-23 |
| CA2942549A1 (en) | 2015-09-24 |
| AU2015231713B2 (en) | 2020-11-19 |
| AU2021201118A1 (en) | 2021-03-11 |
| KR20220157516A (ko) | 2022-11-29 |
| AU2024205254A1 (en) | 2024-10-03 |
| MX380767B (es) | 2025-03-12 |
| KR20160132459A (ko) | 2016-11-18 |
| JP2022141868A (ja) | 2022-09-29 |
| EP3119810A1 (en) | 2017-01-25 |
| KR20250006995A (ko) | 2025-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016011975A (es) | Metodos para reducir el riesgo cardiovascular. | |
| MX2020009246A (es) | Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular. | |
| MX379286B (es) | INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe). | |
| MX2017000628A (es) | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. | |
| MX2016004580A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| EA201691320A1 (ru) | Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2018002000A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| AR105712A1 (es) | Composiciones de insulina de rápida acción | |
| MX2019003703A (es) | Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| MX374749B (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer. | |
| MX2022013081A (es) | Compuestos para el tratamiento de sars. | |
| MX2017009122A (es) | Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. | |
| CL2021001623A1 (es) | Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer | |
| CO2021005797A2 (es) | Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia | |
| AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
| CO2019005207A2 (es) | Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabética | |
| AR103636A1 (es) | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol | |
| ZA202005282B (en) | Use of pcsk9 inhibitor for reducing cardiovascular risk | |
| AR097590A1 (es) | Métodos para tratar el síndrome del x frágil y trastornos relacionados | |
| AR097179A1 (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y flupirtina |